Asukamycin
Based on 1 Customer Validation
Asukamycin, a manumycin-type metabolite, could be isolated from Streptomyces nodosus subsp. asukaensis. Asukamycin is an antibiotic and has antimicrobial activity. Asukamycin inhibits growth of various tumor cell lines.
For research use only. We do not sell to patients.
- Purity : 95.0%
- CAS No.: 61116-33-4
- Formula: C31H34N2O7
- Molecular Weight:546.61
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Antibiotic Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCC38 | EC50 |
4.5 μM
Compound: Asukamycin
|
Antiproliferative activity against human HCC38 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Antiproliferative activity against human HCC38 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 37984298] |
| MDA-MB-231 | EC50 |
13.8 μM
Compound: Asukamycin
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 37984298] |
In Vitro
Asukamycin (1-50 μM; 24 h) in a concentration-dependent manner reduces viability of five different human cell lines with IC50 of 1-5 μM[1].
Asukamycin (50 μM; 24 and 72 h; THP-1 cells) causes a significant increase in intracellular caspase 8 and caspase 3 activity[1].
Asukamycin (0-100 mcg/mL; bacteria, 18 h; fungus, 72 h) has antimicrobial activity. Asukamycin inhibits the growth of Gram-positive bacteria within a concentration range of 0.78-12.5 mcg/mL and inhibits the growth of Trichophyton mentagrophytes at a concentration of 25 mcg/ mL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human myeloid THP-1, HL-60, U-118 MG, U-87 MG and U-937 cells
-
Concentration:1-50 μM
-
Incubation Time:24 hours
-
Result:Reduced viability of five different cell lines in a concentration-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice[2]
-
Dosage:0-450 mg/kg
-
Administration:Intraperitoneal injection
-
Result:Had no effect on mice when administered by 450 mg/kg and the acute toxicity (LD50) was 48.5 mg/kg by intraperitoneal injection.
Chemical Information
-
CAS No. 61116-33-4
-
Appearance Solid
-
Molecular Weight 546.61
-
Formula C31H34N2O7
-
Color Light yellow to yellow
-
SMILES
O=C1[C@@H]2[C@H]([C@@](O)(C=C1NC(/C=C/C=C/C=C/C3CCCCC3)=O)/C=C/C=C/C=C/C(NC4=C(CCC4=O)O)=O)O2
-
Structure Classification
-
Initial Source
Streptomyces nodosus subsp. asukaensis.
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shipley PR, et, al. Antitumor activity of asukamycin, a secondary metabolite from the actinomycete bacterium Streptomyces nodosus subspecies asukaensis. Int J Mol Med. 2009 Nov;24(5):711-5. [Content Brief]
[2]. Omura S, et, al. A new antibiotic,, asukamycin, produced by Streptomyces. J Antibiot (Tokyo). 1976 Sep;29(9):876-81. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Asukamycin Related Classifications
HY-118893 Related Classifications
Powered by Bioz